Terms: = Thyroid cancer AND PDCD1LG2, Q9BQ51, 80380, ENSG00000197646, MGC142240, Btdc, PDCD1L2, CD273, B7DC, MGC142238, PD-L2, PDL2, bA574F11_2 AND Clinical Outcome
212 results:
1. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
2. The relationship between thyroid peroxidase antibody and differentiated thyroid cancer: a systematic review and meta-analysis.
Zhang H; Tian L; Wang X; Shi X
Front Endocrinol (Lausanne); 2024; 15():1349041. PubMed ID: 38476675
[TBL] [Abstract] [Full Text] [Related]
3. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
6. thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
7. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract] [Full Text] [Related]
8. The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study.
Zuhur SS; Aggul H; Avci U; Erol S; Tuna MM; Uysal S; Akbaba G; Kilinc F; Catak M; Tekin S; Ozturk BO; Yavuz HC; Kadioglu P; Cinar N; Bayraktaroglu T; Topcu B; Altuntas Y; Elbuken G
Endocrine; 2024 Mar; 83(3):700-707. PubMed ID: 37736822
[TBL] [Abstract] [Full Text] [Related]
9. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy.
Wang C; Lu G; Li Y; Liu X; Wang G; Lu C; Li J; Luo Q; Zhang Q; Sun M; Wang X; Wang R
Front Endocrinol (Lausanne); 2023; 14():1217092. PubMed ID: 37600705
[TBL] [Abstract] [Full Text] [Related]
10. No Association of Preablation Thyroglobulin Antibody Positivity and outcome in Pediatric Patients With Papillary thyroid Carcinoma.
Xu Y; Shi L; Wu J; Li H; Wang Y; Liu B
Clin Nucl Med; 2023 Sep; 48(9):763-767. PubMed ID: 37385237
[TBL] [Abstract] [Full Text] [Related]
11. Incidentally detected 18 F-FDG PET-CT-avid thyroid nodules in patients with advanced malignancy: long-term oncological outcomes from a single-centre retrospective cohort.
Owens C; Fitzhugh A; Harrington K; Paleri V; Sharma B; Shur J; Ap Dafydd D
Nucl Med Commun; 2023 Sep; 44(9):810-815. PubMed ID: 37272278
[TBL] [Abstract] [Full Text] [Related]
12. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
[TBL] [Abstract] [Full Text] [Related]
13. Magnetic resonance diagnosis of laryngeal chondritis after transoral laser microsurgery for laryngeal cancer.
Cunha B; Lancini D; Rondi P; Ravanelli M; Maroldi R; Paderno A; Zigliani G; Bertotto I; Piazza C; Farina D
Acta Otorhinolaryngol Ital; 2023 Feb; 43(1):32-41. PubMed ID: 36860148
[TBL] [Abstract] [Full Text] [Related]
14. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract] [Full Text] [Related]
15. Do Histologically Aggressive Subtypes of Papillary thyroid Microcarcinoma have Worse clinical outcome than Non-Aggressive Papillary thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study.
Zuhur SS; Aggul H; Avci U; Erol S; Tuna MM; Uysal S; Akbaba G; Kilinç F; Catak M; Tekin S; Bilen OI; Öztürk BO; Erden EB; Elbuken G; Yavuz HC; Kadioglu P; Cinar N; Kutluturk F; Bayraktaroglu T; Topçu B; Arslan AI; Gucer H; Cihangiroglu G; Topal CS; Ozturk T; Tekin L; Artas G; Akcay E; Gun BD; Altuntas Y
Horm Metab Res; 2023 May; 55(5):323-332. PubMed ID: 36764327
[TBL] [Abstract] [Full Text] [Related]
16. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract] [Full Text] [Related]
17. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of factors influencing the clinical outcome after surgery and
Li Y; Rao M; Zheng C; Huang J; Fang D; Xiong Y; Yuan G
Front Endocrinol (Lausanne); 2022; 13():1015798. PubMed ID: 36313750
[TBL] [Abstract] [Full Text] [Related]
19. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract] [Full Text] [Related]
20. clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis.
Yin L; Hou S; Hou LL; Pu CC
Endocrine; 2023 Feb; 79(2):331-341. PubMed ID: 36207552
[TBL] [Abstract] [Full Text] [Related]
[Next]